ClinicalTrials.gg
RecruitingNCT07764237Updated Aug 19, 2026

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

A Phase 1 interventional study of mRNA-1365 (Profile 2) and mRNA-1345 (Profile 1) in Respiratory Syncytial Virus (RSV) and Human Metapneuomovirus (hMPV), sponsored by ModernaTX, Inc.. Recruiting at 10 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)
  • Human Metapneuomovirus (hMPV)

Keywords

  • Respiratory Syncytial Virus (RSV)
  • Human Metapneuomovirus (hMPV)
  • Vaccine
  • Moderna
  • Respiratory Viral Infection
  • mRNA-1365 (Profile 2)
  • Older Adults
03

In context

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history and physical examination.
  • within the range 18.5 to 35 kg/m2 (inclusive).

Key Exclusion Criteria:

  • History of anaphylaxis or severe reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic, or any components of an mRNA vaccine or therapeutic.
  • Abnormal screening clinical laboratory values for total white blood cell count, , hematocrit, , aspartate aminotransferase, creatinine, alkaline phosphatase, or total >Grade 1, or ≥Grade 1.
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
  • History of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infectious disease.
  • Participants with immune-mediated () conditions are generally excluded.
  • Received a licensed RSV vaccine or participated in a study in which vaccines against RSV and/or hMPV were administered to participants alone, or as part of a combination vaccine, at any time in the past.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    mRNA-1365 (Profile 2) Dose Level 1

    Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 1 on Day 1.

    Biological: mRNA-1365 (Profile 2)

  • Experimental
    mRNA-1365 (Profile 2) Dose Level 2

    Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 2 on Day 1.

    Biological: mRNA-1365 (Profile 2)

  • Experimental
    mRNA-1365 (Profile 2) Dose Level 3

    Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 3 on Day 1.

    Biological: mRNA-1365 (Profile 2)

  • Active comparator
    mRNA-1345 (Profile 1)

    Participants will receive 1 injection of mRNA-1345 (Profile 1) on Day 1.

    Biological: mRNA-1345 (Profile 1)

  • Active comparator
    mRNA-1345 (Profile 3)

    Participants will receive 1 injection of mRNA-1345 (Profile 3) on Day 1.

    Biological: mRNA-1345 (Profile 3)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 7 (the day of study intervention and 6 subsequent days)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 28 (the day of study intervention and 27 subsequent days)

  3. Number of Participants with Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), Any AEs Leading to Study Discontinuation, and AEs of Special Interest (AESIs)

    Time frame: Up to End of Study (EOS) (Day 181)

Secondary outcomes

  1. Geometric Mean Level of Serum Neutralizing Antibodies (nAbs)

    Time frame: Day 29

  2. Geometric Mean Fold Rise (GMFR) of Serum Neutralizing Antibodies (nAbs)

    Time frame: Day 29

  3. Percentage of Particpants with Seroresponse Based on Serum Neutralizing Antibodies (nAbs) Level

    Time frame: Day 29

07

Study locations

2 of 10 sites recruiting
  • Diex Recherche Quebec
    Québec, Quebec G1V 4T3, Canada
    Recruiting
  • Diex Recherche Victoraville
    Victoriaville, Quebec G6P 3Z8, Canada
    Recruiting
  • MAC Clinical Research
    Manchester, Greater Manchester M13 9NQ, United Kingdom
    Not yet recruiting
  • Southampton General Hospital, NHS
    Southampton, Hampshire SO16 6YD, United Kingdom
    Not yet recruiting
  • Norfolk and Norwich University Hospital, NHS
    Norwich, Norfolk NR4 7UQ, United Kingdom
    Not yet recruiting
  • University Hospital Birmingham, NHS
    Birmingham, West Midlands B15 2TH, United Kingdom
    Not yet recruiting
  • Royal Free Hospital, NHS
    London, NW3 2QG, United Kingdom
    Not yet recruiting
  • Guys and St. Thomas Hospital, NHS
    London, SE1 7EH, United Kingdom
    Not yet recruiting
  • St. George University Hospital, NHS
    London, SW17 0RE, United Kingdom
    Not yet recruiting
  • Royal Victoria Infirmary, NHS
    Newcastle, NE1 4LP, United Kingdom
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 13, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Jul 20, 2027
CompletionEst.
Jul 20, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07764237
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Aug 13, 2026
Start date
Aug 11, 2026
Primary completion
Jul 20, 2027 (estimated)
Completion
Jul 20, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Moderna WeCareTeam
Contact
WeCareClinicalTrials@modernatx.com
1-866-663-3762

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion